Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...
Product Name : Addyi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable